Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Elkridge, Maryland Clinical Trials

A listing of Elkridge, Maryland clinical trials actively recruiting patient volunteers.

RESULTS

Found (13) clinical trials

VR for Joint Attention Support in ASD

The study will be a Phase II randomized controlled trial in which the Floreo VR Joint Attention Module is the intervention being evaluated. Floreo is a mobile application that offers a supervised virtual reality experience for individuals with ASD. The application provides a 3D immersive scene for Google Cardboard-compatible smartphones ...

Phase

4.24 miles

Learn More »

Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer

This is a single-center, single arm, open-label phase II study evaluating the safety, anti-tumor effect, and immunogenicity of neoadjuvant Dupixent given prior to radical prostatectomy in men with high-risk localized prostate cancer (this trial will enroll men with at least high risk prostate cancer defined by NCCN Guidelines Version 2.2017 ...

Phase

5.05 miles

Learn More »

Impact of Guided Care With the Vectra DA Multi-biomarker Disease Activity (MBDA) Blood Test

Nine months multi-center prospective, site randomized, two arm trial to evaluate the effect of MBDA score-guided care on disease activity and medical costs. To investigate whether treatment decisions guided by MBDA scores result in reduced disease activity and overall medical cost among patients with RA relative to usual care (UC).

Phase N/A

5.93 miles

Learn More »

An Efficacy and Safety Trial of Fedratinib in Subjects With DIPSS Intermediate or High-Risk Primary Myelofibrosis Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

This is Single-Arm, Open-Label Efficacy and Safety Trial of Fedratinib in Subjects with DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High- Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF), or Post-Essential Thrombocythemia Myelofibrosis (post-ET MF) and Previously Treated with Ruxolitinib. The primary objective of the study is to evaluate ...

Phase

6.15 miles

Learn More »

Treatment of Opioid Use: Medication Adherence Therapy

Residential detox is an ideal opportunity for initiation of relapse prevention medication, particularly XRNTX, which requires some delay after recent opioid use. But concerns from the field emphasize barriers to induction (as highlighted by the recent results of the CTN51 XBOT study), poor adherence and retention. Clarification is needed on ...

Phase N/A

6.47 miles

Learn More »

Evaluation of the Safety Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study

This is a phase 1, 2 part, double-blind (sponsor-unblinded), randomized, placebo-controlled, FTIH study in a combined single-ascending and multiple-ascending dose to assess the safety, tolerability, and PK/pharmacodynamics (PD) attributes of GSK3732394 in healthy subjects. The data gathered in this study will further enable clinical development of GSK3732394 in HIV-infected subjects. ...

Phase

7.51 miles

Learn More »

A Study of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Participants

The purpose of this study is to evaluate the safety and tolerability of a single subcutaneous (SC) dose of JNJ-26366821.

Phase

7.51 miles

Learn More »

A Study to Evaluate the Safety Pharmacokinetics Pharmacodynamics and Immunogenicity of PRV-3279 in Healthy Subjects

PRV-3279-1b is a Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRV-3279 in Healthy Subjects. Eligible subjects include healthy male or female adults, 18 to 50 years of age. Each subject will receive the assigned treatment over 29 days followed ...

Phase

7.51 miles

Learn More »

Robotic Rehabilitation of Cerebral Palsy

Children with spastic CP will be randomly placed to 2 groups, either a Lab group or a Home group. For both groups, the participation will involve 18 training sessions over 6 weeks with 3 sessions each week. Each training session will last about 45 minutes, including stretching and active movement ...

Phase N/A

9.19 miles

Learn More »

Recovery and Outcomes From Stroke

Stroke is the third leading cause of death and the leading cause of adult disability in the United States. More adults are affected by stroke each year than Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis or Parkinson's disease. Hemorrhagic strokes represent the most severe subtypes of stroke. An estimated 40-50% ...

Phase N/A

9.19 miles

Learn More »